GlaxoSmithKline Biologicals

29 trials 7 recruiting Commercial sponsor

Filter these 29 trials by condition, phase, country and more.

Open in Search →
29 Registered trials
7 Recruiting
23 Completed trials
18 Countries active
42 Unique IMPs
100% Results reported
Phase III: 11 Phase II: 8 Phase I/II: 1 Phase III/IV: 1 Phase IV: 2 Phase I: 1 Phase I (FiH): 5
Oversight events:
1 corrective measure across 1 trial
View oversight register →
100%

23 of 23 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Respiratory syncytial virus infection 5 Pneumonia respiratory syncytial viral 2 Meningitis meningococcal 2 Respiratory syncytial virus bronchitis 2 Respiratory syncytial virus bronchiolitis 2 Dementia 1 Influenza 1 Herpes zoster 1

Top IMPs

RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E 7 GSKVX000000025896 4 VARICELLA VIRUS OKA/MERCK STRAIN, (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS 4 RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E 3 VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED) 3 GSKVX000000008866 2 GSKVX000000008885, GSKVX000000017033 2 GSKVX000000009151 2 GSKVX000000034794, GSKVX000000034798, GSKVX000000048110, GSKVX000000048111, GSKVX000000070248, GSKVX000000070250 2 INFLUENZA A VIRUS SUBTYPE H1N1 HAEMAGGLUTININ, RECOMBINANT, INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT, INFLUENZA A VIRUS SUBTYPE H3N2 HAEMAGGLUTININ, RECOMBINANT 2 INFLUENZA INACTIVATED SPLIT VIRUS STRAIN A (H1N1), INFLUENZA INACTIVATED SPLIT VIRUS STRAIN A (H3N2), INFLUENZA INACTIVATED SPLIT VIRUS STRAIN B 2 INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022) 2

All trials — page 2

29 total

Showing 25–29 of 29 trials

← All sponsors A–Z